logo-loader

AstraZeneca drug successfully negotiates final-stage clinical trial

Published: 07:43 24 Sep 2018 BST

diabetes on a dial
Heart failure is an early and frequent complication of diabetes

AstraZeneca (LON:AZN) drug Farxiga successfully negotiated a large phase III trial of people with type-2 diabetes.

DECLARE-TIMI 58 involved 17,000 patients with the disease. The AZ treatment had a statistically significant impact on hospitalisation for heart failure and cardiovascular death in the group studied.

“The results from this landmark trial are especially important since heart failure is an early and frequent complication of diabetes and associated with hospitalisations that result in a considerable societal and economic burden,” said Elisabeth Björk, head of AZ’s cardiovascular operation.

FTSE rises ahead of Easter weekend, JD Sport gains on upbeat outlook -...

The FTSE 100 gained on the final morning of this shortened Easter trading week. Festive cheer was limited though, as Thames Water confirmed shareholders would not provide it with a £500 million rescue package, prompting speculation over the London supplier’s future. On a more positive...

44 minutes ago